Design and Synthesis of Hsp90 Inhibitors with B-Raf and PDHK1 Multi-Target Activity

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Multi-target ligand design offers a promising strategy for treating complex diseases like cancer.
• Combined inhibition of Hsp90 and B-Raf has shown synergistic anti-cancer effects.
• PDHK1 plays a crucial role in tumor progression and senescence, with an ATP-binding pocket similar to Hsp90.

Purpose of the Study:

• To design and synthesize novel compounds targeting Hsp90, B-Raf, and PDHK1 simultaneously for cancer treatment.
• To explore the potential benefits of inhibiting these three targets concurrently.

Main Methods:

• Utilized molecular docking to assemble and integrate molecular fragments targeting Hsp90, PDHK1, and B-Raf.
• Synthesized a library of designed compounds.
• Performed in vitro assays to evaluate the inhibitory activity of the synthesized compounds.
• Conducted molecular dynamics simulations to understand the structural basis of the multi-target activity.

Main Results:

• Compounds 4a, 4d, and 4e demonstrated potent inhibition of Hsp90.
• These compounds also exhibited moderate inhibition of PDHK1 kinase.
• Molecular dynamics simulations provided insights into the structural mechanisms of their multi-target action.

Conclusions:

• The designed multi-target ligands show potential for cancer therapy by simultaneously inhibiting Hsp90 and PDHK1.
• This approach offers a novel strategy for developing more effective cancer treatments.
• Further research into these compounds could lead to new therapeutic interventions.